Caveolin 3

Subscribe to Selected New Research on Caveolin 3

90 relevant articles (1 outcomes, 4 trials/studies) found for this Bio-Agent

Description: A caveolin that is expressed exclusively in MUSCLE CELLS and is sufficient to form CAVEOLAE in SARCOLEMMA. Mutations in caveolin 3 are associated with multiple muscle diseases including DISTAL MYOPATHY and LIMB-GIRDLE MUSCULAR DYSTROPHY.

Also Known As:

Caveolin-3; M-Caveolin; Muscle Caveolin; Caveolin, Muscle

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Lisanti, Michael P: 5 articles (09/2005 - 01/2002)
2.	Oka, Naoki: 3 articles (03/2005 - 08/2003)
3.	Imaizumi, Tsutomu: 3 articles (03/2005 - 08/2003)
4.	Galbiati, F: 3 articles (10/2001 - 08/2000)
5.	Lisanti, M P: 3 articles (10/2001 - 08/2000)
6.	Ishikawa, Yoshihiro: 2 articles (01/2008 - 12/2004)
7.	Tester, David J: 2 articles (02/2007 - 11/2006)
8.	Ye, Bin: 2 articles (02/2007 - 11/2006)
9.	Makielski, Jonathan C: 2 articles (02/2007 - 11/2006)
10.	Ackerman, Michael J: 2 articles (02/2007 - 11/2006)

Related Diseases

1.	Neoplasms (Cancer) 02/01/2009 - "Loss of caveolin-3 induces a lactogenic microenvironment that is protective against mammary tumor formation." 01/01/2002 - "Samples with high levels of caveolin-3 tended to have higher degrees of tumor-infiltrating immune cells, although this finding was not statistically significant. " 01/01/2002 - "Tumor-infiltrating immune cells were also studied immunohistochemically, and the correlation between the number of immune cells and caveolin-3 concentrations was calculated. " Order ALL the reference details at left...
2.	Limb-Girdle Muscular Dystrophies (Limb-Girdle Muscular Dystrophy) 01/15/2004 - "The current study characterized the biochemical and cardiac parameters of P104L mutant caveolin-3 transgenic mice, a model of an autosomal dominant limb-girdle muscular dystrophy (LGMD1C). " 07/01/2008 - "Loss of caveolin-3, resulting from dominant negative mutations of caveolin-3 causes autosomal dominant limb-girdle muscular dystrophy (LGMD) 1C and autosomal dominant rippling muscle disease (AD-RMD). " 05/01/2007 - "A deficiency in caveolin-3 (Cav-3), the major striated muscle isoform, is responsible for skeletal muscle disorders, such as limb-girdle muscular dystrophy 1C (LGMD 1C). " 11/01/2006 - "Dominant-negative mutations of the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy 1C (LGMD1C) with loss of caveolin-3. " 09/10/2006 - "Caveolin-3 is a muscle-specific caveolin isoform that is deficient in limb girdle muscular dystrophy type 1 C (LGMD1C). " Order ALL the reference details at left...
3.	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 10/01/2003 - "Thus, caveolin-3 transgenic and null mice represent valid mouse models to study Duchenne muscular dystrophy (DMD) and LGMD-1C, respectively, in humans. " 11/01/2003 - "In contrast, we have demonstrated that overexpression of caveolin-3 in skeletal muscle tissue promotes defects similar to those seen in Duchenne muscular dystrophy (DMD). " 10/01/2003 - "Modulation of myoblast fusion by caveolin-3 in dystrophic skeletal muscle cells: implications for Duchenne muscular dystrophy and limb-girdle muscular dystrophy-1C." 10/01/2001 - "By contrast, upregulation of the caveolin-3 protein is associated with Duchenne muscular dystrophy (DMD). " 08/15/2000 - "It recently was reported that Duchenne muscular dystrophy (DMD) patients and mdx mice have elevated levels of caveolin-3 expression in their skeletal muscle. " Order ALL the reference details at left...
4.	Inflammation 10/01/2006 - "In the present study, gene expression profiles, analyzed in the skeletal muscles of caveolin-3 deficient mice using the DNA microarray technique, showed that the gene of osteopontin, a versatile regulator of inflammation and tissue repair, was significantly down-regulated. " 01/01/2009 - "Ovariectomized Wistar rats consuming a high-sodium diet received one of four treatments (n=7 per group): group 1, placebo pellets; group 2, E(2) (0 x 5 mg/pellet, 21-day release); group 3, NOS inhibitor, N(omega)-nitro-L-arginine-methyl-ester (L-NAME; 40 mg/kg per day for 14 days) plus Ang II (0 x 225 mg/kg per day on days 11-14); group 4, E(2) plus L-NAME/Ang II. E(2) increased cardiac levels of estrogen receptors ESR1 and ESR2, an ESR-associated membrane protein caveolin-3, eNOS, and phosphorylated (p)eNOS, thus, exerting potentially beneficial cardiovascular effects on NO. However, E(2) also increased cardiac levels of proteins associated with cardiovascular injury and inflammation including, AT(1)R, protein kinase C delta (PRKCD), phosphorylated PRKC, and phosphorylated extracellular signal regulated kinase (pMAPK)3/1, plasminogen activator inhibitor-1 (PAI-1), osteopontin and ED-1, a monocyte/macrophage-specific protein. " Order ALL the reference details at left...
5.	Testicular Neoplasms (Testicular Cancer) 01/01/2002 - "The aim of this study was to examine the expressions of caveolin-1 and caveolin-3 (which is a caveolin-1 homologue localized predominantly in muscle tissue) in testicular cancer. " 01/01/2002 - "METHODS: We evaluated the expressions of caveolin-1, caveolin-3, and iNOS in 16 seminoma and 10 non-seminoma testicular cancer specimens as well as normal testicular tissue, using a streptavidin-biotin bridge technique on cryostat sections. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Caveolin 1
2.	Osteopontin
3.	DNA (Deoxyribonucleic Acid)
4.	Dystrophin
5.	Sodium
6.	Membrane Proteins (Integral Membrane Proteins)
7.	Nitric Oxide Synthase Type I (Neuronal Nitric Oxide Synthase)
8.	Sarcoglycans (beta Sarcoglycan)
9.	Dystroglycans (Dystroglycan)
10.	Nitric Oxide Synthase (NO Synthase)

Related Therapies and Procedures

1.	Ovariectomy (Oophorectomy)

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 20112 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>